Kirkland's Client Strategy Pays Off In Teva's Bid For Mylan
Kirkland & Ellis LLP's representation of Teva Pharmaceuticals Ltd. in the generic-drug maker's $50 billion bid on Tuesday to buy Mylan NV is the latest in a long line of matters the...To view the full article, register now.
Already a subscriber? Click here to view full article